Piramal Pharma Receives FDA Form 483 With VAI Observations at U.S. Plant

Piramal Pharma Limited announced that the U.S. FDA conducted a Good Manufacturing Practices inspection at its Sellersville facility, resulting in a Form 483 with three Voluntary Action Indicated observations. The findings did not involve data integrity, and the company plans to respond promptly while collaborating with the regulator. This indicates limited immediate regulatory risk, but highlights the need for ongoing compliance in the pharmaceutical sector to reassure investors and customers about product quality. Piramal Pharma operates globally, focusing on manufacturing pharmaceutical products under stringent standards.